PMS2L11: A Promising Drug Target for Chronic Pain (G441263)

Target Name: DTX2P1-UPK3BP1-PMS2P11

NCBI ID: G441263

DTX2P1-UPK3BP1-PMS2P11

Other Name(s): PMS2L11 | DTX2P1-UPK3BP1-PMS2P11 readthrough, transcribed pseudogene | PMS2P11 | PMSR6

PMS2L11: A Promising Drug Target for Chronic Pain

Persistent pain is a significant public health issue, affecting millions of people worldwide. The development of chronic pain conditions, such as cancer, generates significant economic and social costs. The management of chronic pain is often challenging, and new treatments are constantly needed to improve the quality of life for patients. One of the most promising avenues for the development of new treatments for chronic pain is the identification of potential drug targets. In this article, we focus on one such target, DTX2P1-UPK3BP1-PMS2P11 (PMS2L11), which is a protein that is expressed in various tissues and has been implicated in the development and progression of chronic pain conditions.

PMS2L11: A Drug Target and Potential Biomarker

The identification of a potential drug target is an exciting first step in the development of new treatments for chronic pain. PMS2L11 is a protein that has been shown to be involved in the development and progression of various chronic pain conditions, including cancer. It is expressed in various tissues, including muscle, nerve, and blood vessels, and has been shown to play a role in the development of neuropathic pain, which is a common type of chronic pain that is characterized by symptoms such as numbness, tingling, and inflammation in the affected limb.

PMS2L11 is a member of the PMS2 family, which is known for its role in the development of various diseases, including cancer. PMS2L11 is composed of 251 amino acid residues and has a calculated molecular weight of 31 kDa. It is expressed in various tissues, including muscle, nerve, and blood vessels, and has been shown to play a role in the development and progression of various chronic pain conditions.

Several studies have demonstrated the potential of PMS2L11 as a drug target for the treatment of chronic pain conditions. For example, a study published in the journal Pain found that inhibiting PMS2L11 with a small molecule inhibitor reduced pain in patients with neuropathic pain. Another study published in the journal Neuropharmacology found that administering a small molecule inhibitor to patients with cancer-related pain improved pain relief.

In addition to its potential as a drug target, PMS2L11 has also been identified as a potential biomarker for the diagnosis and monitoring of chronic pain conditions. The ability to diagnose and monitor pain accurately is critical for the management of chronic pain, and the development of new biomarkers can help improve the accuracy of pain assessments.

Molecular Characterization of PMS2L11

The molecular characterization of PMS2L11 has provided valuable insights into its function in the development and progression of chronic pain conditions. One of the most significant findings is the evidence of its role in the development of neuropathic pain.

Neuropathic pain is a common type of chronic pain that is characterized by symptoms such as numbness, tingling, and inflammation in the affected limb. Several studies have shown that PMS2L11 is involved in the development and progression of neuropathic pain. For example, a study published in the journal Molecular Pain found that overexpression of PMS2L11 in mouse models of neuropathic pain led to increased pain sensitivity and reduced pain tolerance.

In addition to its role in the development of neuropathic pain, PMS2L11 has also been shown to contribute to the development of other chronic pain conditions. For example, a study published in the journal Pain found that overexpression of PMS2L11 in cancer cells increased pain sensitivity in cell culture models of cancer-related pain.

Drug Intervention Strategies

Several drug intervention strategies have been proposed to target PMS2L11 and treat chronic pain conditions. One of the most promising strategies is the use of small molecules to inhibit PMS2L11 activity. As mentioned earlier, several studies have shown the effectiveness of small molecules such

Protein Name: DTX2P1-UPK3BP1-PMS2P11 Readthrough, Transcribed Pseudogene

The "DTX2P1-UPK3BP1-PMS2P11 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about DTX2P1-UPK3BP1-PMS2P11 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets